These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [The breakthrough of personalized medicine, new hopes and new challenges]. Flippot R; Massard C; Auclin E; Azria D; Bourien H; Rochigneux P; Schernberg A; Verlingue L; Zafrani L; Vignot S Bull Cancer; 2017 Sep; 104(9):735-743. PubMed ID: 28807365 [TBL] [Abstract][Full Text] [Related]
6. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Pérez-Herrero E; Fernández-Medarde A Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885 [TBL] [Abstract][Full Text] [Related]
7. Precision cancer medicine: the future is now, only better. Tsimberidou AM; Eggermont AM; Schilsky RL Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061 [TBL] [Abstract][Full Text] [Related]
8. Evidence-based laboratory medicine in oncology drug development: from biomarkers to diagnostics. Modur V; Hailman E; Barrett JC Clin Chem; 2013 Jan; 59(1):102-9. PubMed ID: 23034140 [TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomic biomarkers for personalized cancer treatment. Rodríguez-Antona C; Taron M J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550 [TBL] [Abstract][Full Text] [Related]
10. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview. Lin PS; Semrad TJ Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315 [TBL] [Abstract][Full Text] [Related]
11. Value-Based Medicine and Integration of Tumor Biology. Brooks GA; Bosserman LD; Mambetsariev I; Salgia R Am Soc Clin Oncol Educ Book; 2017; 37():833-840. PubMed ID: 28561700 [TBL] [Abstract][Full Text] [Related]
12. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia. Molloy MP; Engel A Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786 [No Abstract] [Full Text] [Related]
13. Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Beckman RA; Clark J; Chen C Nat Rev Drug Discov; 2011 Sep; 10(10):735-48. PubMed ID: 21959287 [TBL] [Abstract][Full Text] [Related]
14. New science-based endpoints to accelerate oncology drug development. Kelloff GJ; Sigman CC Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552 [TBL] [Abstract][Full Text] [Related]
15. Precision medicine in pediatric oncology. Forrest SJ; Geoerger B; Janeway KA Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430 [TBL] [Abstract][Full Text] [Related]
16. Qualification of imaging biomarkers for oncology drug development. Waterton JC; Pylkkanen L Eur J Cancer; 2012 Mar; 48(4):409-15. PubMed ID: 22226478 [TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic biomarkers in model-based drug development in oncology. Keizer RJ; Schellens JH; Beijnen JH; Huitema AD Curr Clin Pharmacol; 2011 Feb; 6(1):30-40. PubMed ID: 21235464 [TBL] [Abstract][Full Text] [Related]
18. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Amacher DE Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512 [TBL] [Abstract][Full Text] [Related]
19. Surrogate markers in oncology practice and anticancer drug development: lessons learned from antiretroviral therapy? Remick SC Cancer Invest; 2004; 22(1):164-8. PubMed ID: 15069775 [No Abstract] [Full Text] [Related]
20. Molecular markers, molecular-targeted therapies and taxanes: how to integrate the progress into clinical research and practice for the management of head and neck cancers. Awada A; Lalami Y Curr Opin Oncol; 2005 May; 17(3):209-11. PubMed ID: 15818162 [No Abstract] [Full Text] [Related] [Next] [New Search]